| Literature DB >> 25994175 |
Xinyu Zhao1, Jun Qin2, Yang Tan3, Rahul Mohanan4, Dongcai Hu5, Liaobin Chen6.
Abstract
BACKGROUND: Total knee arthroplasty (TKA) has been reported to be the most successful treatment for patients with advanced osteoarthritis, however, early postoperative pain has become an unresolved issue. The aim of this Meta-analysis is to evaluate the efficacy and safety of steroid addition to multimodal cocktail periarticular injection (MCPI) in patients undergoing TKA.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25994175 PMCID: PMC4443605 DOI: 10.1186/s13018-015-0214-8
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Fig. 1Flow chart summarizing the selection process of randomized control trials
Details on the included studies in the meta-analysis
| Author | Year of publication | Sample size | Patient mean age | Sex (M/F) | BMI | Steroid/control group | Drain/blocks/anesthesia | Cocktail | Steroid Used | Administration Method | Type of Knee arthroplasty | Other intervention protocol |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kwon | 2014 | 76 | 69.3 | 0/76 | 25.9 | 76/76 | ?/none/SA | 10 mg morphine, 300 mg ropivacaine,30 mg ketorolac, 300 μg of 1:1000 epinephrine | 40 mg Triamcinolone | SLIA IAPC | Cemented TKA | Preoperative celecoxib, ultracet,pregabalin |
| Unresurfaced patella | Postoperative PCA | |||||||||||
| Yue | 2013 | 72 | 69.75 | 8/64 | 25.685 | 36/36 | All drains/none/GA | 0.75 % ropivacaine 30 ml, 1:1000 adrenaline 0.5 ml | 7 mg Betamethasone | SLIA IAPC | TKA(unclassified) | |
| Postoperative PCA, celecoxib | ||||||||||||
| Ikeuchi | 2014 | 40 | 76.5 | 6/34 | ? | 20/20 | All drains/none/GA | 20 ml of 0.75 % ropivacaine, 400 mg of isepamicin | 6.6 mg Dexamethasone | Peri-articular tissues | Cemented TKA | |
| Unresurfaced patella | Postoperative PCA, loxoprofen | |||||||||||
| Chia | 2013 | 127 | 66.93 | ? | 31.15 | 84/43 | None/none/SA | 0.2 % ropivacaine and 100 ml 1:1000 adrenaline | Triamcinolone | SLIA IAPC | Cemented TKA, | |
| 40 mg in subgroup1, 80 mg in subgroup2 | Resurfaced patella | Postoperative celecoxib | ||||||||||
| Seah | 2011 | 100 | 66.65 | ? | 27 | 50/50 | ?/none/SA or GA | 0.5 ml/kg of 1:200,000 epinephrine and 0.5 % bupivacaine | 40 mg of Triamcinolone | SLIA IAPC | Cemented TKA, | |
| Postoperative PCA | ||||||||||||
| Christensen | 2009 | 76 | 65.508 | 23/53 | 33.9 | 39/37 | ?/FNB/GA | 80 mg of bupivacaine, 4 mg morphine, 300 mg epinephrine, 100 mg clonidine, 750 mg cefuroxime | 40 mg Methylprednisolone | SLIA IAPC | TKA(unclassified) | Preoperative elecoxib, oxycodone or acetaminophen |
SA Spinal Anesthesia, GA General Anesthesia, SLIA IAPC, Systematic Infiltration Including Anterior and Posterior Capsule, TKA Total knee Arthroplasty, PCA Patient Controlled Analgesia, FNB, Femoral Nerve Block, ? Unknown
12-item scale critical appraisal scores
| Author | 12-item scale critical appraisal score | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Total | |
| Kwon 2014 [ | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 12 |
| Yue 2013 [ | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 12 |
| Ikeuchi 2014 [ | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 12 |
| Chia 2013 [ | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 12 |
| Seah 2011 [ | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | 11 |
| Christensen 2009 [ | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | 11 |
12-item scale criteria: (1) Method of randomization; (2) Concealed allocation; (3) Patient blinding; (4) Provider blinding; (5) Outcome assessor blinding; (6) Drop-out rate; (7) Patient allocated as plan; (8) Free of selective outcome reporting; (9) Same baseline; (10) Co-interventions avoided or similar; (11) Acceptable compliance; (12) Same time of outcome assessment. Y = Yes, N = No, A trial with a score of seven or more was considered high quality, more than four but no more than seven was considered moderate quality, and no more than four was considered low quality
Comparison of postoperative pain VAS scores between the steroid and control group
| Postoperative period | Weighted mean of VAS in the steroid group | Weighted mean of VAS in the control group | WMD | [95 % CI] |
|
| Selected model | Overall | |
|---|---|---|---|---|---|---|---|---|---|
| Night of operation | 2.270 | 2.888 | −0.328 | −0.914 | 0.258 | 0.006 | 80.3 % | Random-effects model | 0.272 |
| Day 1 | 3.362 | 3.805 | −0.630 | −1.321 | 0.061 | 0.001 | 87.1 % | Random-effects model | 0.074 |
| Day 2 | 2.354 | 2.865 | −0.300 | −0.504 | −0.096 | 0.249 | 28.0 % | Fixed-effects model | 0.004 |
| Day 3 | 2.394 | 2.882 | −0.568 | −0.868 | −0.268 | 0.194 | 36.3 % | Fixed-effects model | 0.001 |
| Day 7 | 2.264 | 2.693 | −0.310 | −0.496 | −0.125 | 0.520 | 0 % | Fixed-effects model | <0.001 |
Fig. 2Comparison of knee ROM between the steroid and control group at the first postoperative day
Fig. 3Comparison of knee ROM between the steroid and control group on the second postoperative day
Fig. 4Comparison of knee ROM between the steroid and control group on the third postoperative day
Fig. 5Comparison of knee ROM between the steroid and control group at 3 months postoperatively
Fig. 6Comparison of postoperative drainage between the steroid and control group
Fig. 7Comparison of the period of time required to perform a straight-leg raise between the steroid and control group
Fig. 8Comparison of the length of hospital stay between the steroid and control group
Fig. 9Comparison of the rate of postoperative infection between the steroid and control group
Fig. 10Comparison of the rate of postoperative wound oozing between the steroid and control group